



CASE RECORD FORM INSTRUCTIONS

SEVERE ACUTE RESPIRATORY INFECTION CLINICAL CHARACTERISATION DATA TOOLS

DESIGN OF THIS CASE RECORD FORM (CRF)

This CRF is divided into 4 main forms: a "RAPID" (page 1) form with basic admission and outcome data; a "CORE" form with more detailed presentation (pages 2-3) and outcome (pages 4-6) data; a "DAILY" form (page 7) for daily laboratory and clinical data; and a set of "SUPPLEMENTARY" (Page 8-14) forms for overflow data, study-specific inclusion criteria and other investigations. These forms should be used in one of the defined combinations below according to the site's resource availability and scientific interests.

HOW TO USE THIS CRF

Each site may choose the amount of data to collect based on available resources and the number of patients enrolled to date. Ideally, data on patients presenting early in an outbreak will be collected using the Tier 2 schedule of forms outlined below. The decision is up to the site Investigators and may be changed throughout the data collection period. All high quality data is valuable for analysis.

Tier 0 – Complete the RAPID CRF only – For low resource sites or, during an epidemic, sites that have already enrolled large numbers of patients on the Tier 1/2 schedule.

Tier 1 – Complete the CORE CRF + complete the DAILY CRF on the first day of hospital admission and the first day of ICU admission (note: this could be the same day) – For sites that do not have the resources to collect the level of daily data in Tier 2.

Tier 2 - Complete the CORE CRF + complete the DAILY CRF on the first 2 days of hospital admission and the first 2 days of all ICU admissions. — For sites with available resources.

Additional CRF modules are available (e.g. study-specific inclusion criteria, epidemiology) to be completed in addition to any of the Tiers above according to the objectives of the site. If you would like access to additional CRFs, or to suggest a new module for inclusion in these forms please contact us at the email below.

GENERAL GUIDANCE

- The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected retrospectively if the patient is enrolled after the admission date.
- Participant Identification Numbers consist of a 3-digit network code, a 3 digit site code and a 4 digit participant number. You can obtain a network code and site code by registering on the data management system at www.cliresdms.org by contacting isaric@oucru.org. Participant numbers should be assigned sequentially for each site beginning with 0001. In the case of a single site recruiting participants on different wards, or where it is otherwise difficult to assign sequential numbers, it is acceptable to assign numbers in blocks or incorporating alpha characters. E.g. Ward X will assign numbers from 0001 or A001 onwards and Ward Y will assign numbers from 5001 or B001 onwards. Enter the Participant Identification Number at the top of every page.
- Data may be entered to the central database at www.cliresdms.org or to your site/network's independent database.
- In the case of a participant transferring between study sites, it is preferred to maintain the same Participant Identification Number across the sites. When this is not possible, space for recording the new number is provided.
- Complete every line of every section, except for where the instructions say to skip a section based on certain responses.
- Selections with square boxes () are single selection answers (choose one answer only). Selections with circles () are multiple selection answers (choose as many answers as are applicable).
- Mark 'N/A' for any results that are not available, not applicable or unknown. For laboratory values, enter 'N/A' in the data space when results are not available, not applicable or unknown.
- Avoid recording data outside of the dedicated areas. Sections are available for recording additional information.
- We recommend writing clearly in ink, using BLOCK-CAPITAL LETTERS.
- Place an (X) when you choose the corresponding answer. To make corrections, strike through (-----) the data you wish to delete and write the correct data above it. Please initial and date all corrections.
- Please keep all of the sheets for a single participant together e.g. with a staple or participant-unique folder.
- Please enter data on the electronic data capture system at <u>www.cliresdms.org</u>. If your site would like to collect data independently, we are happy to support the establishment of locally hosted databases.
- Please contact us at isaric@oucru.org if we can help with databases, if you have comments and to let us know that you are using the forms.

RAPID CASE RECORD FORM - Severe Acute Respiratory Infection





PARTICIPANT IDENTIFICATION #:	[_][_	_][_	_]-[_	_][_	_][_	_][_	_]

This is the RAPID clinical data form for use in Tier 0 data collection only. Complete sections 1-3 at admission. Complete section 4 for ICU admission (if applicable). Complete sections 5&6 after discharge/death/transfer. Enter data to the database at www.cliresdms.org

Clinical centre name: Country:
Enrolment date: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] 3. DEMOGRAPHICS
2. DEMOGRAPHICS Sex at Birth:
If birth date unknown: Estimated age [][]years OR [][]months
Pregnant? LYES LNO LUnknown LN/A If YES: Gestational weeks assessment: [][] weeks
3. ONSET & ADMISSION
Symptom onset date of first/earliest symptom: [_D_](_D_]/(_M_](_M_]/(_2_](_0_](_Y_](_Y_]
Admission date at this facility: [_D_](_D_]/[_M_](_M_]/[_2_][_0_](_Y_](_Y_]
4. INTENSIVE CARE OR HIGH DEPENDENCY CARE UNIT ADMISSION
ICU admission (or high dependency unit)? \(\text{TES} (complete the rest of this section) \)
First ICU admission date: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]
Record the worst value in first 24 hours of first ICU admission:
Mechanical ventilation YES NO N/A FiO ₂ (0.21-1.0) [].[] or [][]L/min
SaO_2 at time of $FiO_2[$ $][$ $][$ $]\%$ PaO_2 at time of $FiO_2[$ $][$ $][$ $]$ \square kPa or \square mmHg
Platelet Count [][]x10 9/L
Glasgow Coma Score (GCS / 15): [][] Urine flow rate [][][]mL/24 hours - Check if estimated
Record the highest value in first 24 hours of first ICU admission:
Total Bilirubin [][]μmol/L Creatinine [][][] μmol/L or \Box mg/dL
Vasopressor/inotropic support on 1 st day of ICU admission? \[\text{VES} \] NO (if NO, answer the next 3 questions NO) \[\text{N/A} \] Dopamine <5 \(\text{μg/kg/min OR Dobutamine OR Milrinone OR Levosimendan:} \] Dopamine 5-15 \(\text{μg/kg/min OR Epinephrine/Norepinephrine} \) <0.1 \(\text{μg/kg/min OR vasopressin OR phenylephrine:} \] Dopamine >15 \(\text{μg/kg/min OR Epinephrine/Norepinephrine} \) > 0.1 \(\text{μg/kg/min:} \] Most recent ICU discharge date: \[\text{D} \] \[\text{D} \] \[\text{M} \] \[\te
Influenza: VES- Confirmed VES- Probable NO If YES: A/H3N2 A/H1N1pdm09 A/H7N9 A/H5N1 B
Dother:
Coronavirus: 🗆 ES- Confirmed 🗖 ES- Probable 🗀 NO If YES: 🗆 MERS-CoV 🗀 bther:
Other: 🗖 ES- Confirmed 🗖 ES- Probable 🗖 NO If YES: 🗖 other:
Clinical pneumonia: \(\sum_{YES} \) \(\sum_{NO} \) If NONE OF THE ABOVE: Unknown/Non-infective: \(\sum_{YES} \)
6. OUTCOME
During hospital admission did the patient at <i>any</i> time receive: Oxygen therapy: YES NO N/A Invasive ventilation YES NO N/A Non-invasive ventilation: YES NO N/A
ECMO/ECLS: YES NO N/A Dialysis: YES NO N/A Multiple ICU admissions: YES NO N/A
Outcome: Alive at discharge Hospitalization Transfer to other facility Death Palliative discharge N/A

CORE CASE RECORD FORM - Severe Acute Respiratory Infection





PARTICIPANT IDENTIFICATION #:	[]	l[_1[_1-	[]	[][_	1[1
	L	J L	-J L	-9		LJ L-	J L	-1

Outcome date: $[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]$

This is the CORE Data Form for use in Tier 1 and Tier 2 data collection. Complete CORE PRESENTATION sections 1-3 at admission. Enter data at www.cliresdms.org

1. DEMOGRAPHICS									
Clinical centre name:				Country:					
Enrolment date: [_D_][_D_]/[_M_][_	M_]/[_2_][_0_][<u>Y_][_Y_]</u>						
Sex at Birth: Male emale	Birth dat	e: [_ <u>D</u> _][_D_]/[_M_][M]/[Y][Y][Y]					
	f birth da	ate unk	nown: Estin	nated age [][][]years OR [_][]mo	nths			
Pregnant? ☐/ES ☐NO ☐Jnknow	rn □N/A	4	If YES: 0	Gestational weeks assessment: [][] weeks	□N/A	١		
Admission weight (whole number) [][_][_]	□kg or	·□lbs □N/	A Height : [][]□cm <i>or</i> □inch	es □N/A				
If age <5 years: Mid-upper-arm circumference [][]mm									
Ethnic group (check all that apply): O	Arab C	Black	O East As	ian OSouth Asian OWest Asian	O Latin A	merica	n		
0	White C	D Abori	ginal/First N	ations OOther:			□N/A		
Admission date at this facility: <code>_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]</code>									
Transfer from other facility? □YES-facility is a study site □YES-facility is not a study site □NO □N/A									
If YES: Name of transfer facility:									
If YES: Admission date at transfer	facility (DD/MM/	'YYYY): [<u>D</u>][D]/[M][M]/[2][0][Y][Y]	□N/A				
If YES-Study Site: Participant # at t	ransfer f	acility:	□Same as a	bove Different: [][]-[_][][_	_][] □N/A		
Travel in the 14 days prior to first syn	nptom or	set?	□YES □N	O □N/A					
If YES, state location(s) & date(s):	Country:			City/Geographic area:	 				
Return Date: [_D_][_D_]/[_M_][_	<u>M</u> _]/[_2	_][_0_]	[_Y_][_Y_]	□ N/A (more space on SUPPLEMENTARY DATA	FORM)				
Contact with animals, raw meat or in □YES □NO □ N/A If YES, complete				or to symptom onset? (see SUPPLEMENTARY DATA FORM).					
2. CO-MORBIDITIES & RISK FA	CTORS (existing F	PRIOR TO ADMI	SSION & that are active problems)					
Chronic cardiac disease (not hypertension)	□YES	□NO	□N/A	Metastatic solid tumour	□YES	□NO	□N/A		
Chronic pulmonary disease (not asthma)	□YES	□NO	□N/A	Malignant neoplasm (including leukaemia & lymphoma)	□YES	□NO	□N/A		
Asthma (physician diagnosed)	□YES	□NO	□N/A	AIDS / HIV	□YES	□NO	□N/A		
Chronic kidney disease	□YES	□NO	□N/A	Obesity (as defined by clinical staff)	□YES	□NO	□N/A		
Moderate or severe liver disease	□YES	□NO	□N/A	Diabetes with complications	□YES	□NO	□N/A		
Mild liver disease	□YES	□NO	□N/A	Rheumatologic disorder	□YES	□NO	□N/A		
Chronic neurological disorder	□YES	□NO	□N/A	Dementia	□YES	□NO	□N/A		
Hemiplegia / Paraplegia	□YES	□NO	□N/A						

CORE CASE RECORD FORM - Severe Acute Respiratory Infection





PARTICIPANT IDENTIFICATION #:	ſ	11	11	1-1	П	11	11	1
THE THE PROPERTY OF THE PROPERTY OF THE	L	-J L	-J L	-J L-	J L	J L	J L	J

2. CO-MORBIDITIES & RISK F	ACTORS continued									
Recurrent fever prior to admission	n? □Yes □No □N/A									
Malaria diagnosis after symptom o	onset? □YES □NO □N/A									
		ed) corticosteroids prior to admission? section of the SUPPLEMENTARY DATA F								
Treatment with anti-infectives for this illness episode prior to admission? □YES □NO □N/A If YES, complete the ADMISSION ANTI-INFECTIVES section of the SUPPLEMENTARY DATA FORM.										
POST PARTUM? □YES □NO or N/A (skip this section - go to INFANT)										
Pregnancy Outcome: □Live bir	th □Still birth	Delivery date : [_D_][_D_]/[_M_][_	M_]/[_2_][_0_][_Y_][_Y_]							
Baby tested for Mom's infection	on? □YES □NO □N/A If	YES: □Positive □Negative Method:	□PCR □Other:							
INFANT – Less than 1 year old?	YES □NO (skip this section	n) Birth weight: [][].[]□k	g or □lbs □N/A							
Gestational outcome: ☐ Term b	oirth (≥37wk GA) □Prete	rm birth (<37wk GA) □N/A								
Breastfed? □YES □NO □N/	A If YES: □Currently b	reastfed Breastfeeding discontinued	d at [][]weeks □N/A							
Appropriate development for age? □YES □NO □N/A Vaccinations appropriate for age/country? □YES □NO □N/A										
Other relevant risk factor(s):										
3. SIGNS AND SYMPTOMS AT HOSPITAL ADMISSION (first available data at presentation/admission – within 24 hours)										
Symptom onset date (first/earliest	Symptom onset date (first/earliest symptom): [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]									
Temperature: [][].[_]□°C <i>or</i> □°F HR: [][][]beats per minute RR: [_][]breaths per minute							
Systolic BP: [][]mmHg	Diastolic	BP: [][]mmHg								
Severe dehydration? □YES □NO		rapillary refill time >2 seconds? \square YES								
_	•		LINO LINA							
Oxygen saturation: [][][]% On: □Room air □O:	xygen therapy □N/A								
Admission signs and symptoms	s (observed/reported at add	mission and associated with this episodo	e of acute illness)							
History of fever	□YES □NO □N/A	Lower chest wall indrawing	□YES □NO □N/A							
Cough	□YES □NO □N/A	Headache	□YES □NO □N/A							
with sputum production	□YES □NO □N/A	Altered consciousness/confusion	□YES □NO □N/A							
bloody sputum/haemoptysis	□YES □NO □N/A	Seizures	□YES □NO □N/A							
Sore throat	□YES □NO □N/A	Abdominal pain	□YES □NO □N/A							
Runny nose (Rhinorrhoea)	□YES □NO □N/A	Vomiting / Nausea	□YES □NO □N/A							
Ear pain	□YES □NO □N/A	Diarrhoea	□YES □NO □N/A							
Wheezing	□YES □NO □N/A	Conjunctivitis	□YES □NO □N/A							
Chest pain	□YES □NO □N/A	Skin rash	□YES □NO □N/A							
Muscle aches (Myalgia)	□YES □NO □N/A	Skin ulcers	□YES □NO □N/A							
Joint pain (Arthralgia)	□YES □NO □N/A	Lymphadenopathy	□YES □NO □N/A							
Fatigue / Malaise	□YES □NO □N/A	Bleeding (Haemorrhage)	□YES □NO □N/A							

CORE CASE RECORD FORM - Severe Acute Respiratory Infection





PARTICIPANT IDENTIFICATION #:	[]][][_	_]-	[_][_][_	_][_]
-------------------------------	----	----	-----	-----	---	-----	------	-----	----

This is the CORE Data Form for use in Tier 1 and Tier 2 data collection. Complete CORE OUTCOME sections 4-8 after discharge/death/transfer.

4. COMPLICATIONS: At any time dur				he patient experience:			•
Viral pneumonitis	□YES	□NO	□N/A	Cardiac arrest	□YES	□NO	□N/A
Bacterial pneumonia	□YES	□NO	□N/A	Bacteraemia	□YES	□NO	□N/A
Acute lung injury / Acute Respiratory Distress Syndrome	□YES	□NO	□N/A	Coagulation disorder / Disseminated Intravascular Coagluation	□YES	□NO	□N/A
Pneumothorax	□YES	□NO	□N/A	Anaemia	□YES	□NO	□N/A
Pleural effusion	□YES	□NO	□N/A	Rhabdomyolysis / Myositis	□YES	□NO	□N/A
Bronchiolitis	□YES	□NO	□N/A	Acute renal injury/ Acute renal failure	□YES	□NO	□N/A
Meningitis / Encephalitis	□YES	□NO	□N/A	Gastrointestinal haemorrhage	□YES	□NO	□N/A
Seizure	□YES	□NO	□N/A	Pancreatitis	□YES	□NO	□N/A
Stroke / Cerebrovascular accident	□YES	□NO	□N/A	Liver dysfunction	□YES	□NO	□N/A
Congestive heart failure	□YES	□NO	□N/A	Hyperglycemia	□YES	□NO	□N/A
Endocarditis / Myocarditis / Pericarditis	□YES	□NO	□N/A	Hypoglycemia	□YES	□NO	□N/A
Cardiac arrhythmia	□YES	□NO	□N/A	Other	□YES	□NO	□N/A
Cardiac ischaemia	□YES	□NO	□N/A	Specify:			

5. PATHOGEN TES	TING: Was pathogen testing done during this	s illness episode? □\	'ES (complete se	ction) □NO □N/A
Collection Date (DD/MM/YYYY)	Biospecimen Type	Laboratory Test Method	Result	Pathogen Tested/Detected
//20	□Nasal/NP swab □Throat swab □Combined nasal/NP+throat swab □Sputum □BAL □ETA □Urine □Feces/rectal swab □Blood □Other, Specify:	□PCR □Culture □Other, Specify:	□Positive □Negative □N/A	
//20	□Nasal/NP swab □Throat swab □Combined nasal/NP+throat swab □Sputum □BAL □ETA □Urine □Feces/rectal swab □Blood □Other, Specify: □	□PCR □Culture □Other, Specify:	□Positive □Negative □N/A	
//20	□Nasal/NP swab □Throat swab □Combined nasal/NP+throat swab □Sputum □BAL □ETA □Urine □Feces/rectal swab □Blood □Other, Specify:	□PCR □Culture □Other, Specify:	□Positive □Negative □N/A	
//20	□Nasal/NP swab □Throat swab □Combined nasal/NP+throat swab □Sputum □BAL □ETA □Urine □Feces/rectal swab □Blood □Other, Specify:	□PCR □Culture □Other, Specify:	□Positive □Negative □N/A	
//20	□Nasal/NP swab □Throat swab □Combined nasal/NP+throat swab □Sputum □BAL □ETA □Urine □Feces/rectal swab □Blood □Other, Specify: □	□PCR □Culture □Other, Specify:	□Positive □Negative □N/A	

CORE CASE RECORD FORM - Severe Acute Respiratory Infection





PARTICIPANT IDENTIFICATION #: [][_	_][]-[_	_][_	_][_	_][_]
---------------------------------	-----	-----	------	------	------	-----	----

6. TREATMENT: At ANY time during hospitalisation, did the patient receive/undergo:								
ICU or High Dependency Unit admission? □YES □NO □N/A If YES, total num	ber of ICU/HDU admissions:	_						
If YES: First admission date: <code>_D_](_D_]/(_M_](_M_]/(_2_](_0_](_Y_](_Y_) </code>	If YES, total duration:days	;						
Most recent discharge date: $[_D_](_D_]/[_M_](_M_]/[_2_][_0_](_Y_](_Y_]$	I/A							
Oxygen therapy? □YES □NO □N/A	If YES, total duration:days	;						
If YES: First/Start date: [_D_](_D_]/(_M_](_M_]/(_2_](_0_](_Y_](_Y_)								
Last/End date: [_D_](_D_]/(_M_](_M_]/(_2_](_0_](_Y_](_Y_) □N/A								
Non-invasive ventilation? (e.g. BIPAP, CPAP) □YES □NO □N/A	If YES, total duration: days	;						
Invasive ventilation (Any)? □YES □NO □N/A	If YES, total duration:days							
If YES: First/Start date: [_D_](_D_]/(_M_](_M_]/(_2_](_0_](_Y_](_Y_)								
Last/End date: $[D][D]/[M][M]/[2][0][Y][Y]$								
Oscillatory Ventilation? YES NO N/A	. If YES, total duration:days							
Prone Ventilation? □YES □NO □N/A	. If YES, total duration:days							
Inhaled Nitric Oxide?	If YES, total duration:days							
Extracorporeal membrane oxygenation (ECMO) or interventional lung-assist therapy (iL	A)?							
□ECMO □iLA □None □Not available at site □N/A	If YES, total duration: day	S						
If YES: First/Start date: [_D_](_D_]/(_M_](_M_]/(_2_](_0_](_Y_](_Y_)								
Last/End date: $[D][D]/[M][M]/[2][0][Y][Y]$								
Renal replacement therapy (RRT) or dialysis? □YES □NO □N/A	If YES, total duration: days	S						
If YES: First/Start date: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]								
Last/End date: $[D][D]/[M][M]/[2][0][Y][Y]$								
Inotropes/vasopressors?	If YES, total duration:days	S						
If YES: First/Start date: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] □N/A								
Last/End date: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]								
Plasmapheresis/exchange? □YES □NO □N/A Oral rehydration therapy	only? □YES □NO □ N/A							
Intravenous Immunoglobulin? □YES □NO □ N/A Blood transfusion or pro	ducts? YES NO N/A							
OTHER intervention or procedure (please specify):								
7. MEDICATION: While hospitalised or at discharge, were any of the following a	administered ?							
Antiviral agent? □YES □NO □N/A If YES: ONeuraminidase Inhibitors OOther	Antibiotic? □YES □NO □N/	'A						
Corticosteroid? □YES □NO □N/A If YES, Route: OOral OIntravenous OInhaled	Antifungal agent? □YES □NO □N/	/A						
If any of the anti-infectives or corticosteroids listed above were administered, please comp CORTICOSTEROIDS section of the SUPPLEMENTAL DATA FORM.	lete the MEDICATION: ANTI-INFECTIVES	8						
Angiotensin converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARB	s)? □YES □NO □N/A							
Statins (HMG-CoA Reductase Inhibitor)? □YES □NO □N/A If YES: Taking statins prior	to admission? □YES □NO □N/A							

CORE CASE RECORD FORM - Severe Acute Respiratory Infection





PARTICIPANT IDENTIFICATION #: [_	_][_	_][_	_]-[_	_][_	_][_	_][_	_]
----------------------------------	------	------	-------	------	------	------	----

8. OUTCOME
Outcome: Alive at discharge Hospitalization Transfer to other facility Death Palliative discharge N/A
Outcome date: [_D_](_D_]/(_M_](_M_]/(_2_](_0_](_Y_](_Y_)
If Discharged alive: Ability to self-care at discharge versus before illness: □Same as before illness □Worse □Better □N/A
If Discharged alive: Post-discharge treatment:
Oxygen therapy? □YES □NO □N/A Dialysis/renal treatment? □YES □NO □N/A
Other intervention or procedure? □YES □NO □N/A
If YES: Specify (multiple permitted):
If Transferred: Facility name: \square N/A
If Transferred: Is the transfer facility a study site? □YES □NO □N/A
If a Study Site: Participant # at new facility: □Same as above □Different: [][] = [][][] □N/A
If Died: Primary cause of death (one only):
□Multi-organ dysfunction syndrome □Acute lung injury □Pneumonia □Myocardial infarction
□Congestive heart failure □Dysrhythmia □Chronic obstructive lung disease □Pulmonary emboli
□Cerebrovascular disease □Renal failure □Liver failure □Malignant neoplasm
□Other, specify: □N/A
If Died: Secondary cause(s) of death (check all that apply):
OMulti-organ dysfunction syndrome OAcute lung injury OPneumonia OMyocardial infarction
OCongestive heart failure ODysrhythmia OChronic obstructive lung disease OPulmonary emboli
OCerebrovascular disease ORenal failure OLiver failure OMalignancy
OOther, specify:Oother, specify:
Diagnosis (check/complete all that apply):
Influenza:
Coronavirus:
Clinical pneumonia:
Other (1):
Other (2):
Other (3):
If none of the above: Unknown/Non-infective:

DAILY CASE RECORD FORM - Severe Acute Respiratory Infection





PARTICIPANT IDENTIFICATION #:	[_	_][_	_][_	_]-[_	_][_	_][_	_][.]
-------------------------------	----	------	------	-------	------	------	-----	----

Tier 1 - complete DAILY form on first day of hospital admission + first day of ICU/HDU admission. Tier 2 – Complete DAILY form on 1^{st} & 2^{nd} days of hospital admission; 1^{st} & 2^{nd} day of all ICU admissions; and any day that research samples are taken.

1. DATE OF ASSESSMENT (DD/MM/YYYY): [_D_][_D_]/[_M_][_M_]/[_2_][0_][_Y_][_Y_] (may not be the date of completion)							
2. DAILY TREATMENT (complete every line):							
Current admission to ICU/ITU/IMC/HDU? □YES □NO □N/A							
Record the worst value in the previous 24 hours (if Not Available write 'N/A'):							
FiO ₂ (0.21-1.0) [].[] or [][]L/min SaO ₂ [][]%							
PaO₂ at time of FiO₂ above [][]							
From same blood gas record as PaO ₂ PCO ₂ DkPa or DmmHg pH							
HCO ₃ mEq/L Base excessmmol/L							
Glasgow Coma Score (GCS / 15) [][] Mean Arterial Blood Pressure [][]mmHg							
Urine flow rate [][][]mL/24 hours □ Check if estimated							
Is the patient currently receiving, or has received in the past 24 hours (apply to all questions in this section):							
Non-invasive ventilation (eg. BIPAP, CPAP)? □YES □NO □N/A Invasive ventilation? □YES □NO □N/A							
Oscillatory Ventilation? YES NO N/A Extracorporeal membrane oxygenation (ECMO/ECLS)? YES NO N/A							
Interventional lung-assist therapy (iLA)? □YES □NO □N/A Dialysis/Hemofiltration? □YES □NO □N/A							
Any vasopressor/inotropic support?							
Dopamine 5-15 μ g/kg/min OR Epinephrine/Norepinephrine < 0.1 μ g/kg/min OR vasopressin OR phenylephrine: \square YES \square NO Dopamine >15 μ g/k/min OR Epinephrine/Norepinephrine > 0.1 μ g/kg/min:							
Oral rehydration only? □YES □NO □N/A Intravenous Immunoglobulin? □YES □NO □N/A							
Blood transfusion or products? □YES □NO □N/A Plasmapheresis/Exchange? □YES □NO □N/A							
Other intervention or procedure: NO N/A If YES, Specify:							
3. DAILY LABORATORY RESULTS Results available for samples taken on the date in section 1 above? YES (complete below) NO (skip section)							
Haemoglobin □g/L or □g/dL Haematocrit % WBC count □x10 ⁹ /L or □x10 ³ /μL							
Platelets □x10 ⁹ /L or □x10 ³ /μL APTT/APTR PT seconds or INR							
ALT/SGPT U/L Total Bilirubin□μmol/L or □mg/dL C-reactive protein □mg/L or							
□nmol/L							
AST/SGOT U/L Glucose mmol/L or \(\text{mg/dL} \) Erythrocyte Sed Rate mm/h							
Blood Urea Nitrogen (urea) □mmol/L or □mg/d Lactate □mmol/L or □mg/dL							
LDH U/L Creatine kinase CPK U/L Creatinine □µmol/L or □mg/dL							
4. CHEST X-RAY Are results available for a chest x-ray performed on the date in section 1 above?							
Are infiltrates present? □YES □NO □N/A If YES:							
Check all quadrants where infiltrates are present: ORight upper ORight lower OLeft upper OLeft lower □N/A							





PARTICIPANT IDENTIFICATION #	[_	_][][_	_]-	[_	_][_	_][_	_][_	_]
------------------------------	----	-----	-----	-----	----	------	------	------	----

EXTRA SPACE FOR INFORMATION ON THE CORE DATA FORM

Use this form to record information that does not fit the space provided in the CASE REPORT FORM or where detailed. All information from the CASE REPORT FORM and this SUPPLEMENTARY DATA FORM should be entered into the appropriate sections of the electronic CASE REPORT FORM at https://www.cliresdms.org

CORE - SECTION 1 - TRAVEL: Did the patient travel in the 14 days prior to first symptom onset? If > 1 location & date list:									
Country: City/Geogra	phic area:	Return Date (DD/MM/20YY)://20							
Country: City/Geogra	phic area:	Return Date (DD/MM/20YY):/20							
Country: City/Geogra	phic area:	Return Date (DD/MM/20YY):/20							
14 days prior to first symptom onset? Co.	mplete each line below.	live/dead animals, raw meat or insect bites in the ct and date of exposure (DD/MM/YYYY) here:							
Bird/Aves (e.g. chickens, turkeys, ducks)	□YES □NO □N/A								
Bat	□YES □NO □N/A								
Livestock (e.g. goats, cattle, camels)	□YES □NO □N/A								
Horse	□YES □NO □N/A								
Hare/ Rabbit	□YES □NO □N/A								
Pigs	□YES □NO □N/A								
Non-human primates	□YES □NO □N/A								
Rodent (e.g. rats, mice, squirrels)	□YES □NO □N/A								
Insect bite (e.g. tick, flea, mosquito)	□YES □NO □N/A								
Reptile / Amphibian	□YES □NO □N/A								
Domestic animals living in his/her home (e.g. cats, dogs, other)	□YES □NO □N/A								
Animal feces or nests	□YES □NO □N/A								
Sick animal or dead animal	□YES □NO □N/A								
Raw animal meat / animal blood	□YES □NO □N/A								
Skinned, dressed or eaten wild game	□YES □NO □N/A								
Visit to live animal market, farm or zoo	□YES □NO □N/A								
Participated in animal surgery or necropsy	□YES □NO □N/A								
Other animal contacts:	□YES □NO □N/A								





PARTICIPANT IDENTIFICATION #:	[]][.][_	.]-	[.][][_	_][_	_]
-------------------------------	----	----	------	-----	---	-----	-----	------	----

EXTRA SPACE FOR INFORMATION ON THE CORE DATA FORM - CONTINUED

Use this form to record information that does not fit the space provided in the CASE REPORT FORM or where detailed. All information from the CASE REPORT FORM and this SUPPLEMENTARY DATA FORM should be entered into the appropriate sections of the electronic database at https://www.cliresdms.org

Name of immunosuppressa	ant Dose and free	quency	Route of	administrat	ion	Duration
		□unknown	□IV □C	Oral □Inhal N/A	ed	□days □w □
		□unknown	□IV □0	Oral □Inhal N/A	ed	□days □w □
		□unknown		Dral □Inhal	ed	□days □w □
		□unknown		Dral □Inhal	ed	□days □w □
		□unknown		Oral □Inhal	ed	□days □w □
CORE - SECTION 2 – ADMISS		Treated wit	th anti-infecti	ves (antibio	tics and anti-v	irals) for this illness
Name of medication	Dose and frequency	Stor	t date	Enc	l date	Route of
(generic name preferred)	Dose and frequency		M/20YY)		M/20YY)	administration
generic name prejeneaj	□N/A	(DD) IVI	141/2011/	(00)10	On-going	□IV □Oral □Inh
	ШіўА	,	/20	,	/20	□Other □N//
	□N/A	/				
		,	/20	,	/20	□Other □N//
	□N/A	/				□IV □Oral □Inh
		,	/20	/	/20	□Other □N//
	□N/A				On-going	□IV □Oral □Inh
	,	/	/20	/	/20	□Other □N//
	□N/A				On-going	□IV □Oral □Inh
	,	1	/20	/	/20	□Other □N//
ORE – ADDITIONAL INFOR	MATION: Detail any add	litional infor	mation not co	ptured in the	e CASE REPOR	T FORM.





PARTICIPANT IDENTIFICATION #: [][.][]-	·[][_	_][][_	_]
-----------------------------------	-------	-------	--------	----

EXTRA SPACE FOR INFORMATION ON THE CORE DATA FORM - CONTINUED

Use this form to record information that does not fit the space provided in the CASE REPORT FORM or where detailed . All information from the CASE REPORT FORM and this SUPPLEMENTARY DATA FORM should be entered into the appropriate sections of the electronic database at https://www.cliresdms.org

CORE - SECTION 5 -PATHOGEN TESTING: Results of pathogen testing done during this illness episode.							
Sample Collection Date (DD/MM/YYYY)	Biospecimen Type	Laboratory Test Method	Result	Pathogen			
//20	□Nasal/NP swab □Throat swab □Combined nasal/NP+throat swab □Sputum □BAL □ETA □Urine □Feces/rectal swab □Blood □Other, Specify:	□PCR □Culture □Other, Specify:	□Positive □Negative □N/A				
//20	□Nasal/NP swab □Throat swab □Combined nasal/NP+throat swab □Sputum □BAL □ETA □Urine □Feces/rectal swab □Blood □Other, Specify:	□PCR □Culture □Other, Specify:	□Positive □Negative □N/A				
//20	□Nasal/NP swab □Throat swab □Combined nasal/NP+throat swab □Sputum □BAL □ETA □Urine □Feces/rectal swab □Blood □Other, Specify:	□PCR □Culture □Other, Specify:	□Positive □Negative □N/A				
//20	□Nasal/NP swab □Throat swab □Combined nasal/NP+throat swab □Sputum □BAL □ETA □Urine □Feces/rectal swab □Blood □Other, Specify:	□PCR □Culture □Other, Specify:	□Positive □Negative □N/A				
//20	□Nasal/NP swab □Throat swab □Combined nasal/NP+throat swab □Sputum □BAL □ETA □Urine □Feces/rectal swab □Blood □Other, Specify: □	□PCR □Culture □Other, Specify:	□Positive □Negative □N/A				
//20	□Nasal/NP swab □Throat swab □Combined nasal/NP+throat swab □Sputum □BAL □ETA □Urine □Feces/rectal swab □Blood □Other, Specify:	□PCR □Culture □Other, Specify:	□Positive □Negative □N/A				
//20	□Nasal/NP swab □Throat swab □Combined nasal/NP+throat swab □Sputum □BAL □ETA □Urine □Feces/rectal swab □Blood □Other, Specify:	□PCR □Culture □Other, Specify:	□Positive □Negative □N/A				





PARTICIPANT IDENTIFICATION #: [][][]	- [1[_	1[_	1[1
-------------------------------------	---	-----	-----	-----	-----

EXTRA SPACE FOR INFORMATION ON THE CORE DATA FORM - CONTINUED

Use this form to record information that does not fit the space provided in the CASE REPORT FORM or where detailed . All information from the CASE REPORT FORM and this SUPPLEMENTARY DATA FORM should be entered into the appropriate sections of the electronic database at https://www.cliresdms.org

l	Dose and frequency			
Name of medication generic name preferred)	(specify or unknown)	Start date (DD/MM/20YY)	End date (DD/MM/20YY)	Route of administration
	□n/a	//20	☐On-going //20	□IV □Oral □Inhale □Other □N/A
	□n/a	//20	☐On-going //20	□IV □Oral □Inhal
	□n/a	//20	☐On-going//20	□IV □Oral □Inhal □Other □N
	□n/a	//20	☐On-going	□IV □Oral □Inha □Other □N
	□n/a	//20	☐On-going //20	□IV □Oral □Inha □Other □N
	□n/A	//20	□On-going //20	□IV □Oral □Inha □Other □N
	□n/a	//20	□On-going //20	□IV □Oral □Inha □Other □N
	□n/a	//20	☐On-going //20	□IV □Oral □Inha □Other □N
	□n/a	/ /20	☐On-going /_0/20	□IV □Oral □Inha □Other □N
	□n/a		☐On-going //20	□IV □Oral □Inha □Other □N
	□n/a	//20	☐On-going //20	□IV □Oral □Inha □Other □N
	□n/a	/ /20	☐On-going /_0/20	□IV □Oral □Inha □Other □I
	□n/a	/ /20	☐On-going /_0/20	□IV □Oral □Inha □Other □I
	□n/a		☐On-going //20	□IV □Oral □Inha □Other □I
	□n/a	//20	☐On-going //20	□IV □Oral □Inha □Other □I
	□n/a	//20	☐On-going //20	□IV □Oral □Inha □Other □N
	□n/a	//20	☐On-going //20	□IV □Oral □Inha □Other □N
	□n/a	//20	□On-going //20	□IV □Oral □Inha □Other □I
	□n/a	//20	□On-going //20	□IV □Oral □Inha □Other □I
	□n/a	//20	☐On-going //20	□IV □Oral □Inha □Other □N
	□n/a	//20	□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	□IV □Oral □Inha □Other □N





PARTICIPANT IDENTIFICATION #:	[][]]	[]-[_	_][][_	_][]

ADDITIONAL EPIDEMIOLOGICAL INVESTIGATIONS (Tier 3)

Investigations additional to those on the CASE REPORT FORMs may be of interest to some sites. Some examples of relevant data are below and can be completed at the discretion of the site. All information should be entered into the appropriate sections of the electronic database at https://www.cliresdms.org

EXPOSURES IN THE PREVIOUS 14 DAYS:			
Confirmed case contact? ☐/ES ☐NO ☐N/A	Probable case contact? WES NO N/A		
Travel? YES NO N/A Animal? YES NO	O N/A Occupational? YES NO N/A		
LIVING ARRANGEMENT: What was the primary living situation	on of the patient in the 14 days before presentation to hospital?		
☐Home. # of people in home (including patient):	☐Military base ☐Correctional institution ☐Shelter		
☐Boarding school/dormitory	□Nursing home/long-term healthcare facility		
□Other:	□N/A		
OCCUPATION: What is the patient's occupation?	□n/a		
	,		
VACCINATION HISTORY:			
Pneumococcal vaccination ever? □Yes □No □N/A If Yes: Age at receipt of pneumococcal vaccine: □ If YES: Type of vaccine: □7-valent conjugate □13- Haemophilus influenzae type b vaccination □Yes □No If Yes, age at receipt of haemophilus vaccine: □ RSV immunization Palivizumab (if applicable) □Yes □No	ior to illness IV (injected)		
Are other vaccines relevant to the infection being studied? If YES: Name of Disease If YES: Has the patient ever been vaccinated against thi If YES: Age at first receipt of vaccine: years If YES: Time since last dose: □≥14 days prior to illness	s disease? No N/A N/A Number of doses received to date: N/A N/A N/A		
Any other relevant details:			





PARTICIPANT IDENTIFICATION #: [][]-	[][_	_][][]
-------------------------------------	------	-------	---

SPRINT SARI INCLUSION CRITERIA				
Suspected or proven acute respiratory infection	□YES	□чо		
New admission with symptom onset within the previous 14 days:	□YES	□чо	(required for inclusion)	
Experience of the following symptoms during this illness episode:			(one or more required for inclusion)	
 A history of feverishness or measured fever of ≥ 38°C: 	YES	□чо		
· Cough:	□YES	□чо		
· Dyspnoea (shortness of breath) OR Tachypnoea*:	□YES	□чо		
* respiratory rate ≥50 breaths/min for <1 year; ≥40 breaths/min for 1-4 years; ≥30 breaths/min for 5-12 years; ≥20 breaths/min for ≥13 years				